Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Denali Therapeutics (DNLI) Leases (2019 - 2025)

Denali Therapeutics (DNLI) has disclosed Leases for 7 consecutive years, with $20.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Leases fell 48.21% to $20.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $20.0 million, a 48.21% decrease, with the full-year FY2024 number at $47.5 million, changed N/A from a year prior.
  • Leases was $20.0 million for Q3 2025 at Denali Therapeutics, down from $47.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $50.2 million in Q1 2025 to a low of $20.0 million in Q3 2025.
  • A 5-year average of $32.4 million and a median of $30.6 million in 2021 define the central range for Leases.
  • Biggest YoY gain for Leases was 98.34% in 2025; the steepest drop was 48.21% in 2025.
  • Denali Therapeutics' Leases stood at $30.7 million in 2021, then decreased by 1.0% to $30.4 million in 2022, then decreased by 12.11% to $26.8 million in 2023, then surged by 77.69% to $47.5 million in 2024, then plummeted by 57.85% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Leases are $20.0 million (Q3 2025), $47.4 million (Q2 2025), and $50.2 million (Q1 2025).